Contact information
Research groups
Colleges
Websites
Claire Edwards
Professor of Bone Oncology
Professor Claire Edwards (née Shipman) obtained a first class honours degree and Ph.D. from the University of Sheffield, where she began her career in cancer-induced bone disease.
Following postdoctoral studies at the University of Sheffield and the University of Oxford, Professor Edwards moved to the United States in 2004 to take up assistant professor positions at the University of Texas Health Science Center at San Antonio and subsequently at Vanderbilt University.
Professor Edwards is the recipient of multiple awards and fellowships, including most recently, the Iain T. Boyle Award from the European Calcified Tissue Society.
Professor Edwards relocated her lab to the University of Oxford in 2010 as a University Lecturer in Bone Oncology, with a joint appointment in NDORMS and the Nuffield Dept. of Surgical Sciences, and a fellowship at St. Edmund Hall.
Research interests are focused upon the pathogenesis of cancer-induced bone disease, including the contributions of the host bone marrow microenvironment and the role of obesity, adipocytes and adipokines.
Key publications
-
Metabolic profiling of prostate cancer in skeletal microenvironments identifies G6PD as a key mediator of growth and survival.
Whitburn J. et al, (2022), Sci adv, 8
-
Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease.
Gooding S. et al, (2019), Nat commun, 10
-
Myeloma Cells Down-Regulate Adiponectin in Bone Marrow Adipocytes Via TNF-Alpha.
Morris EV. et al, (2020), J bone miner res, 35, 942 - 955
-
Diet-induced obesity promotes a myeloma-like condition in vivo.
Lwin ST. et al, (2015), Leukemia, 29, 507 - 510
-
Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer.
Rao SR. et al, (2017), Br j cancer, 116, 227 - 236
Recent publications
-
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma.
Grandclément C. et al, (2024), Nat commun, 15
-
The integrated on-chip isolation and detection of circulating tumour cells
Abusamra SM. et al, (2024), Sensors & diagnostics
-
Antibody-based Imaging of Bioreductive Prodrug Release in Hypoxia
Tosun C. et al, (2023), Jacs au
-
Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma.
Pouleau B. et al, (2023), Blood, 142, 260 - 273
-
Adipocyte autophagy limits gut inflammation by controlling oxylipin and IL-10.
Richter FC. et al, (2023), Embo j